Oftalmologia Vistahermosa S.L.

Burjassot 18 trials 4 recruiting

18 Registered trials

4 Currently recruiting

Organisation

Oftalmologia Vistahermosa S.L.

Location

Burjassot, Spain

Identifier

ORG-100044741

Address

Avinguda De Denia 76, 03013, Spain

Departments

3803: Oftalmología
724009: Oftalmología
NA
OFTALMOLOGIA
Ophtalmology
Ophthalmology
Unit of Macula

Clinical trials at this site (18)

Search interface

A clinical trial to assess the efficacy and safety of ADX-308, a new type of treatment for Geographic Atrophy (GA), an advanced stage of eye… Pending

2025-521779-30-00 Geographic atrophy secondary to age-related macular deg 4
A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age-related macular degeneratio… Pending

2025-523704-77-00 Geographic atrophy secondary to age-related macular deg 4
EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPER-REFLECTIVE MATERIAL Recruiting

2025-522701-38-00 SUBRETINAL HYPERREFLECTIVE MATERIAL 6 2026-02-26
A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration Recruiting

2024-517545-13-00 Neovascular Age-Related Macular Degeneration 11 2025-06-04
A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge… Recruiting

2023-509547-27-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2025-05-22
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting

2022-500747-21-00 Geographic Atrophy 4 2025-02-27
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended

2025-520809-12-00 Diabetic Macular Edema 10 2025-10-16
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration… Ended

2024-515022-88-00 Dry Age-Related Macular Degeneration (AMD) with geograp 5 2025-03-03
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended

2024-510944-30-00 Diabetic Macular Edema 10 2024-11-22
ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Sub… Ended

2024-511482-11-00 Dry Age-Related Macular Degeneration (Dry AMD) 5 2024-11-20
A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine… Ended

2024-516315-24-00 myopia 5 2022-05-27
A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended

2023-507131-38-00 Neovascular Age-Related Macular Degeneration (nAMD) 5 2022-05-16
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended

2023-507130-24-00 Neovascular age-related macular degeneration (nAMD) 5 2021-10-22
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended

2023-506707-25-00 Choroidal neovascularization secondary to pathologic my 5 2024-04-09
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended

2024-515185-13-00 geographic atrophy 5 2022-12-21
A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended

2024-512879-13-00 Neovascular age-related macular degeneration (wet AMD) 5 2021-09-23
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem… Ended

2023-507207-66-00 Diabetic Macular Edema (DME) 5